Loading data for INCY — first visit, this takes a few seconds.
Incyte Corporation (INCY)
NasdaqGS: INCY
· Real-Time Price · USD
125.01
+1.79 (1.45%)
At close: Sep 01, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Incyte Corporation (INCY) Stock Price, Analysis & Data
1.45% (1D)
| Bid | 113.67 |
| Market Cap | 25.9B |
| Revenue (ttm) | 5.82B |
| Net Income (ttm) | 1.61B |
| 0.77 | |
| 7.85 | |
| 16.25 | |
| 14.27 | |
| P/B (ttm) | 4.04 |
| P/S (ttm) | 4.44 |
| Earnings Date | Oct 27, 2026 |
| Ask | 133.49 |
| Volume | 1,170,979 |
| Avg. Volume (20D) | 1,824,534 |
| Open | 124.61 |
| Previous Close | 123.22 |
| Day's Range | 122.50 - 125.14 |
| 52-Week Range | 81.09 - 132.60 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 4, 1993
Employees 2,844
Stock Exchange NasdaqGS
Ticker Symbol INCY
Website https://www.incyte.com
Financial Performance
In 2025, Incyte's revenue was 5.14B, an increase of 21.22% compared to the previous year's 4.24B. Earnings were 1.29B, an increase of 3,844.96%.
Financial StatementsEarnings Surprise
Incyte has released their quarterly earnings on Jul 28, 2026:
- Revenue of $1.67B misses estimates by $0, with 37.72% YoY growth.
- EPS of 3.09 exceeds estimates by 0.94, with 96.82% YoY growth.
Incyte Corporation is scheduled to release its earnings on Oct 27, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2